Biomarker-wise, the observed decrease in serum IGFBP-6 in HCC relative to chronic hepatitis encourages evaluation of IGFBP-6 as an adjunct classifier, but studies must control for underlying etiology, fibrosis stage, and antiviral treatment to avoid confounding axis-level shifts [111]. This evidence concerns the gene IGFBP6 and chronic hepatitis.